Oren Livne

Oren Livne

Partner
Baker & McKenzie LLP

Biography

Oren Livne is a partner in the Corporate & Securities Practice Group and the Life Sciences Industry Group. Prior to beginning his law career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Practice Focus

Oren Livne counsels clients from startups to multinationals on variety of corporate and transactional matters globally, including complex license and collaboration agreements, joint ventures, spin outs, commercial contracts, mergers and acquisitions, and other intellectual property focused transactions. His clients include pharmaceutical, biotech, medical device, consumer product, and technology companies as well as private equity firms. Oren is a guest lecturer at New York University entrepreneurship classes and has authored several intellectual property articles.

Representative Legal Matters

  • H. Lundbeck A/S in its acquisition of Abide Therapeutics, a clinical-stage biopharmaceutical company focusing on multiple indications in neurology and psychiatry, for USD 250 million upfront and up to an additional USD 150 million in development and sales milestones.

Prior to joining the Firm, Oren provided counsel to the following:

  • Shire in its agreement with Mirum Pharmaceuticals pursuant to which Mirum has obtained exclusive global rights to develop and market maralixibat, an oral inhibitor of the apical sodium dependent bile acid transporter, and Shire has received undisclosed financial consideration and an equity position in Mirum.

  • Astellas in its global commercialization agreement with Seattle Genetics Inc. to commercialize enfortumab vedotin.

  • Merck in its up to USD 5.76 billion strategic collaboration with Eisai Co. Ltd. for the worldwide co-development and co-commercialization of Eisai's Lenvima (lenvatinib mesylate).

  • Celgene in its global immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers.

  • AbbVie in its strategic collaboration with Alector to develop and commercialize medicines for the treatment of Alzheimer's disease and other neurodegenerative disorders.

  • Regeneron in its clinical collaboration with ISA Pharmaceuticals B.V., with ISA receiving an upfront payment and an equity investment in exchange for an option for an exclusive global license.

  • Takeda in its collaboration with Ultragenyx to develop and commercialize therapies for rare genetic diseases.

  • Incyte its global strategic collaboration with Merus for the research, discovery, development and commercialization of bispecific antibodies with a focus on immuno-oncology.

  • Amarin in its collaboration agreement with Mochida Pharmaceutical for the development and commercialization of drug products based on the omega-3 acid, EPA, to treat patients at risk of cardiovascular disease.

Professional Associations and Memberships

  • New York State Bar Association
  • New Jersey State Bar Association
  • Licensing Executives Society

Admissions

  • New York~United States
  • New Jersey~United States
  • U.S. Patent and Trademark Office~United States

Education

  • New York University (MBA with distinction) (2012)
  • New York University School of Law (JD) (2012)
  • Rutgers University (BS Chemical Engineering with Highest Honors) (1996)

Languages

  • English